{
    "39156816": {
      "P": "young acne patients",
      "I": "social media information exposure",
      "C": "no comparison mentioned",
      "O": "anxiety"
    },
    "39158749": {
      "P": "homeless individuals, undomiciled and sheltered populations, vulnerable group",
      "I": "teledermatology, dermatologic care, dermatologists",
      "C": "in-person dermatologic care, traditional dermatologic care",
      "O": "improved clinical outcomes, enhanced access to dermatologic care, reduced disparities in healthcare access"
    },
    "39159339": {},
    "39159340": {
      "P": "patients undergoing current recent treatment isotretinoin, athletes undergoing isotretinoin treatment, 25-year-old competitive aerial trapeze artist",
      "I": "isotretinoin",
      "C": "no comparison mentioned",
      "O": "skin fragility, blistering, erosions, delayed wound healing, hypertrophic scarring"
    },
    "39161490": {
      "P": "patients diagnosed with SAPHO syndrome, a 56-year-old woman with progressive back pain, and patients with spinal bone metastases",
      "I": "diagnosis, spinal CT scan, MRI, PET/CT",
      "C": "spinal bone metastases",
      "O": "progressive back pain, hyperdense lesions, bone marrow edema, hypointense T1-weighted imaging, hyperintense T2-weighted imaging, multiple skeletal lesions"
    },
    "39162381": {
      "P": "24-year-old woman",
      "I": "corticosteroid taping, systemic prednisone, adalimumab",
      "C": "surgical management",
      "O": "ulcer re-epithelialization, relapse of keloids"
    },
    "39163914": {
      "P": "humans, HACAT cells",
      "I": "centella asiatica-derived triterpenoids",
      "C": "no comparison mentioned",
      "O": "hacat viability, lactate dehydrogenase (LDH) release"
    },
    "39164814": {
      "P": "gastrointestinal tract, skin, digestive system, skin diseases, acne, psoriasis, atopic dermatitis",
      "I": "supplementation, beneficial bacteria, probiotics, topical administration of probiotics",
      "C": "known positive effect, different favorable effects, accelerated wound healing, suppression of inflammation, lower infection risk, reduced antibiotic requirement",
      "O": "elimination of pathological conditions, favorable impact on management of skin diseases, increased interest in skin microbiome, treatment of skin diseases"
    },
    "39165891": {
      "P": "acne vulgaris patients",
      "I": "isotretinoin",
      "C": "variations serum lipid concentration side effect",
      "O": "psychiatric symptoms suicidal ideation"
    },
    "39165893": {
      "P": "patients with severe acne who are insensitive to conventional therapy, including systemic antibiotics",
      "I": "isotretinoin oral medicine",
      "C": "conventional therapy, including systemic antibiotics",
      "O": "development of acute psychosis"
    },
    "39166269": {
      "P": "children with phosphatase tensin homolog pten hamartoma tumor syndrome (phts) and vascular anomalies",
      "I": "sirolimus, an mtor inhibitor",
      "C": "no comparison mentioned",
      "O": "significant clinical improvement, with no significant adverse effects except mild buccal ulcers and acne"
    },
    "39175550": {
      "P": "patients with rosacea",
      "I": "combination of standard biomedical treatment and traditional Chinese medicine (TCM)",
      "C": "standard biomedical treatment",
      "O": "lowered recurrence rate, clinical symptom scores, and interleukin-37 (IL-37) levels"
    },
    "39177615": {
      "P": "women with polycystic ovary syndrome (PCOS) in childbearing years",
      "I": "manual examination and ultrasound images",
      "C": "normal cyst vs. PCOS cyst",
      "O": "infertility"
    },
    "39179105": {
      "P": "cutibacterium acnes, acne vulgaris",
      "I": "clindamycin, fluoroquinolones",
      "C": "none",
      "O": "antibiotic susceptibility"
    },
    "39180560": {
      "P": "patients with rosacea",
      "I": "595 nm pulsed dye laser (PDL) combination with supramolecular salicylic acid (SSA) treatment",
      "C": "no comparison specified",
      "O": "clinical effects"
    },
    "39180584": {},
    "39182678": {},
    "39184705": {
      "P": "population from the middle east region, specifically the united arab emirates (uae), including patients from a dermatology outpatient clinic in dubai, uae, with varying factors such as age, gender, socioeconomic status, location, climate, and dietary habits",
      "I": "none mentioned",
      "C": "none mentioned",
      "O": "types and frequency of dermatological disorders encountered"
    },
    "39184770": {
      "P": "teenagers, populations",
      "I": "none mentioned",
      "C": "none mentioned",
      "O": "prevalence, inflammatory conditions"
    },
    "39184919": {
      "P": "skin",
      "I": "topical retinoid formulation technology",
      "C": "none",
      "O": "skin irritation"
    },
    "39541587": {
      "P": "us adults, adults without diagnosed diabetes, adults prediabetes, adults diabetes",
      "I": "telemedicine use",
      "C": "diagnosed diabetes, prediabetes",
      "O": "prevalence, differences in telemedicine use"
    },
    "39541630": {
      "P": "patients with type 2 diabetes mellitus (T2DM) from community health service centers",
      "I": "self-management knowledge and attitudes and behaviors",
      "C": "status quo",
      "O": "status quo self-management knowledge attitudes behaviors"
    },
    "DRREDDY1.pdf": {
      "P": "Population from the text: approximately 550 subjects with mild to moderate facial acne vulgaris, aged 12-60 years, both males and females, with a minimum of 9 years of age, and a maximum of 60 years of age, with a clinical diagnosis of facial acne vulgaris, and a Fitzpatrick skin type of I-IV.",
      "I": "Intervention: dfd-03 lotion, a topical treatment containing 0.1% tazarotene, applied twice daily for 12 weeks.",
      "C": "Comparison: vehicle lotion, a placebo treatment.",
      "O": "Outcome: efficacy and safety of dfd-03 lotion compared to vehicle lotion in subjects with mild to moderate facial acne vulgaris, measured by the investigator's global assessment (IGA) scale, lesion counts, and other secondary endpoints."
    },
    "PRGO2.pdf": {
      "P": "Male and female subjects, 12-40 years of age, with a clinical diagnosis of facial acne vulgaris, inflammatory lesion papules and pustules count 20-50, non-inflammatory lesion open and closed comedones count 25-100, and nodulocystic lesions.",
      "I": "Adapalene benzoyl peroxide topical gel 0.3/2.5 (Perrigo UK Finco Limited Partnership) and Epiduo Forte adapalene benzoyl peroxide gel 0.3/2.5 (Galderma Laboratories L.P.)",
      "C": "Vehicle test product (Perrigo UK Finco Limited Partnership)",
      "O": "Mean percent change in baseline inflammatory papules and pustules lesion count, mean percent change in baseline non-inflammatory open and closed comedones lesion count, and proportion of subjects with a clinical response at week 12."
    },
    "TARO.pdf": {
      "P": "healthy males and females aged 12-40 years with facial acne vulgaris",
      "I": "clindamycin phosphate benzoyl peroxide gel 1.2/2.5 (test product) and acanya clindamycin phosphate benzoyl peroxide gel 1.2/2.5 (reference product)",
      "C": "vehicle control treatment",
      "O": "lesion count, investigator global assessment (iga), and clinical response"
    },
    "PRGO1.pdf": {
      "P": "Population: male and female subjects aged 12-40 years with moderate to severe facial acne vulgaris",
      "I": "Intervention: Clindamycin phosphate benzoyl peroxide topical gel 1.2/3.75 (Perrigo UK Finco) and Onexton topical gel clindamycin phosphate benzoyl peroxide gel 1.2/3.75 (Valeant Pharmaceuticals North America LLC)",
      "C": "Comparison: Vehicle test product (Perrigo UK Finco) and Onexton topical gel clindamycin phosphate benzoyl peroxide gel 1.2/3.75 (Valeant Pharmaceuticals North America LLC)",
      "O": "Outcome: Efficacy and safety of the study treatments, including inflammatory lesion count, non-inflammatory lesion count, nodulocystic lesion count, and investigator's global assessment"
    },
    "TOLMAR.pdf": {
      "P": "Healthy males and females aged ≥ 12 ≤ 40 years with clinical diagnosis of acne vulgaris, defined as face ≥ 20 facial inflammatory lesions, ≥ 25 non-inflammatory lesions, and ≤ 2 nodulocystic lesions",
      "I": "Clindamycin 1 benzoyl peroxide 5 topical gel, duac topical gel, and vehicle control",
      "C": "Generic innovator clindamycin 1 benzoyl peroxide 5 topical gel and duac topical gel",
      "O": "Mean percent reduction in inflammatory lesion counts, mean percent reduction in non-inflammatory lesion counts, and proportion of subjects achieving at least a 2-grade reduction in acne severity"
    },
    "GandW.pdf": {
      "P": "healthy male non-pregnant female subjects aged ≥ 12 ≤ 40 years age inclusive with clinical diagnosis acne vulgaris",
      "I": "tazarotene cream 0.1 (test product) and tazorac cream 0.1 (reference product)",
      "C": "vehicle placebo cream",
      "O": "percent change in baseline visit 4/week 12 inflammatory lesion counts and non-inflammatory lesion counts, and proportion of subjects with clinical response'success' at visit 4/week 12"
    },
    "TOLMAR1.pdf": {
      "P": "Healthy male and non-pregnant female subjects aged 12-40 years inclusive with clinical diagnosis of acne vulgaris",
      "I": "Clindamycin 1 benzoyl peroxide 5 topical gel (test product) and Benzaclin topical gel (reference product)",
      "C": "Vehicle control treatment (gel placebo)",
      "O": "Mean percent reduction in inflammatory papules and pustules lesion counts, mean percent reduction in non-inflammatory open and closed comedones lesion counts, and proportion of subjects achieving at least a 2-grade reduction in acne severity"
    },
    "PRGO.pdf": {
      "P": "Population: male and female subjects aged 12-40 years with moderate to severe facial acne vulgaris",
      "I": "Intervention: Clindamycin phosphate benzoyl peroxide topical gel 1.2/2.5 and Acanya topical gel",
      "C": "Comparison: Vehicle control treatment",
      "O": "Outcome: Efficacy and safety of the study medications, including inflammatory lesion count, non-inflammatory lesion count, and investigator's global assessment"
    },
    "JDD1.pdf": {
      "P": "patients ≥ 12 years age with moderate-to-severe acne vulgaris",
      "I": "clascoterone cream 1",
      "C": "vehicle cream",
      "O": "favorable long-term safety and efficacy"
    },
    "JDD2.pdf": {
      "P": "Patients aged ≥12 years with moderate-to-severe facial acne vulgaris",
      "I": "Topical clascoterone cream",
      "C": "Vehicle cream",
      "O": "Efficacy and safety outcomes, including proportion of patients achieving treatment success, non-inflammatory lesion count, inflammatory lesion count, and total lesion count"
    },
    "JDD3.pdf": {
      "P": "male and female subjects ≥12 years with facial acne vulgaris",
      "I": "clascoterone 0.1, 0.5, and 1 topical cream",
      "C": "vehicle-controlled dose escalation study",
      "O": "efficacy assessed by investigator's global assessment (IGA), overall severity of acne using a five-point scale, and lesion counts"
    },
    "UCALGARY.pdf": {
      "P": "individuals ≥12 years age with moderate to severe facial acne, including male and non-pregnant female patients, with a slight female predominance (60.6-65.9%) and a majority of white subjects (83%)",
      "I": "clascoterone 1 cream, a novel topical androgen receptor inhibitor",
      "C": "vehicle cream (placebo)",
      "O": "treatment success, reduction in acne lesions, and improvement in acne severity"
    },
    "NCT00988026": {
      "P": "patients with mild to moderate acne",
      "I": "minocycline microgranules and lymecycline",
      "C": "two antibiotic treatments",
      "O": "adverse events profile"
    },
    "NCT03122457": {
      "P": "eligible women age 18 with current therapy for perimenstrual acne",
      "I": "investigational product",
      "C": "no comparison mentioned",
      "O": "acne quality life (acne QOL), subjective assessments, zit count, inflammatory and non-inflammatory acne, global assessment"
    },
    "NCT01929057": {
      "P": "patients with acne",
      "I": "anti-p.acnes antibodies",
      "C": "healthy control patients",
      "O": "reduced inflammation in pimples"
    },
    "NCT01017120": {
      "P": "subjects with acne vulgaris",
      "I": "new foam formulation of tazarotene",
      "C": "none mentioned",
      "O": "safety and efficacy"
    },
    "NCT05517720": {
      "P": "adults with skin-related issues",
      "I": "aria trio complete facial system",
      "C": "no comparison mentioned",
      "O": "reduce wrinkles, reduce skin related issues"
    },
    "NCT01631474": {
      "P": "acne vulgaris androgen-dependent skin disorder",
      "I": "cb-03-01",
      "C": "vehicle treatment",
      "O": "safety efficacy"
    },
    "NCT06202274": {
      "P": "patients with chronic wounds",
      "I": "candela medical technology",
      "C": "no comparison specified",
      "O": "clinical treatment"
    },
    "NCT01289574": {
      "P": "facial acne",
      "I": "topical 0.1 0.025 asc-j9 creams applied twice daily",
      "C": "vehicle control",
      "O": "safety efficacy"
    },
    "NCT01160757": {
      "P": "patients with acute acne lesions",
      "I": "experimental ultrasound device",
      "C": "no comparison mentioned",
      "O": "treating acute acne lesions"
    },
    "NCT03850925": {
      "P": "patients with acne scarring",
      "I": "picosecond 1064-nm laser diffractive lens array nonablative fractional laser treatment",
      "C": "nonablative fractional laser treatment",
      "O": "acne scarring"
    },
    "DRREDDY.pdf": {
      "P": "Population: approximately 550 subjects with mild to moderate facial acne vulgaris, randomized 1:1 ratio to either dfd-03 lotion or vehicle lotion",
      "I": "Intervention: dfd-03 lotion, a topical treatment containing 0.1% tazarotene, applied twice daily for 12 weeks",
      "C": "Comparison: vehicle lotion, a placebo treatment, applied twice daily for 12 weeks",
      "O": "Outcome: primary efficacy endpoints include absolute change in inflammatory and non-inflammatory lesion counts, proportion of subjects with clinical response, and secondary endpoints include percent change in lesion counts and proportion of subjects with 2-grade reduction in lesion counts"
    },
    "TOLMAR2.pdf": {
      "P": "Population: male and female subjects, 12-40 years of age, with clinical diagnosis of acne vulgaris, face defined baseline lesion count ≥ 20 inflammatory lesions ≥ 25 non-inflammatory lesions, two nodulocystic lesions, and acne severity grade 2-4",
      "I": "Intervention: clindamycin phosphate benzoyl peroxide gel 1.2/2.5 (test product) and reference listed drug (RLD) acanya gel",
      "C": "Comparison: vehicle treatment (control arm)",
      "O": "Outcome: bioequivalence, efficacy endpoints (mean percent change in inflammatory papules/pustules lesion count and non-inflammatory open/closed comedones lesion count), and safety endpoints (adverse events, application site reactions)"
    },
    "TOLMAR3.pdf": {
      "P": "Population: male and female subjects aged 12-40 years with acne vulgaris, defined as ≥ 20 facial inflammatory lesions, ≥ 25 facial non-inflammatory lesions, ≤ 2 nodulocystic lesions, and acne severity grade 2-4",
      "I": "Intervention: adapalene 0.1 benzoyl peroxide 2.5 gel, a generic formulation of the reference listed drug (RLD) Epiduo gel",
      "C": "Comparison: vehicle control arm",
      "O": "Outcome: bioequivalence, safety, and efficacy of the test product (adapalene 0.1 benzoyl peroxide 2.5 gel) compared to the RLD (Epiduo gel) using clinical endpoints such as mean percent change in inflammatory and non-inflammatory lesion counts, and proportion of subjects achieving at least a 2-grade reduction in acne severity"
    },
    "TOLMAR4.pdf": {
      "P": "Population: approximately 900 healthy males and females, 12 years of age or older, with clinical diagnosis of acne vulgaris",
      "I": "Intervention: adapalene gel 0.3, generic and branded (Differin)",
      "C": "Comparison: vehicle-controlled trial, comparing the safety and efficacy of generic adapalene gel 0.3 to Differin",
      "O": "Outcome: mean percent change in inflammatory lesions, lesion counts, investigator's global assessment, and adverse events"
    },
    "NCT00620282": {
      "P": "subjects with type 2 diabetes",
      "I": "liraglutide",
      "C": "metformin alone",
      "O": "forearm blood flow"
    },
    "NCT00157482": {
      "P": "diabetic patients, type 2 diabetic patients",
      "I": "ezetimibe, cholesterol-lowering therapy, statins, ezetimibe-simvastatin combined therapy",
      "C": "simvastatin monotherapy",
      "O": "ameliorating lipid profile, albuminuria, decreasing cholesterol concentration"
    },
    "NCT03829982": {
      "P": "obese subjects with impaired fasting glucose and/or impaired glucose tolerance",
      "I": "bright light",
      "C": "none mentioned",
      "O": "postprandial blood glucose metabolism"
    },
    "NCT06453382": {
      "P": "globally non-communicable diseases, bangladesh government, stakeholders involved in ncd-related work",
      "I": "adopting world health organization's comprehensive 'whole-of-government 'whole-of-society approach, multisectoral action plan, tailored intervention model",
      "C": "none mentioned",
      "O": "ncd-specific outcomes"
    },
    "NCT00758082": {
      "P": "type 1 diabetes patients",
      "I": "pda telemonitoring phone",
      "C": "conventional care",
      "O": "hba1c means"
    },
    "NCT01280682": {
      "P": "patients with type 1 diabetes and recent onset",
      "I": "transient elimination of B lymphocytes using anti-CD20 monoclonal antibody",
      "C": "no comparison mentioned",
      "O": "preserved beta-cell function"
    },
    "NCT02422420": {
      "P": "Minnesota Medicaid beneficiaries at high risk of developing diabetes",
      "I": "Two different participant financial incentive structures",
      "C": "None mentioned",
      "O": "Weight loss, diabetes risk, and cardiovascular risk"
    },
    "NCT05580120": {
      "P": "elderly people with type 2 diabetes",
      "I": "online-supervised exercise program",
      "C": "no comparison mentioned",
      "O": "quality of life, psychological resilience, fasting blood sugar"
    },
    "NCT01686620": {
      "P": "patients with type 1 diabetes",
      "I": "biod-123",
      "C": "insulin lispro (Humalog)",
      "O": "safety and efficacy"
    },
    "NCT00252720": {
      "P": "normotensive normoalbuminuric type 1 diabetic patients, type 1 diabetic patients, type 2 diabetic patients",
      "I": "candesartan",
      "C": "placebo",
      "O": "progression diabetic retinopathy, incidence clinically significant macular oedema csme and/or proliferative diabetic retinopathy pdr, rate change urinary albumin excretion rate uaer, incidence microalbuminuria"
    },
    "NCT06214520": {
      "P": "poorly controlled type 2 diabetes mellitus patients",
      "I": "app-based motivational interviewing (MI) with AI-powered personalized nudges delivered through a mobile application (EmpowerPlus)",
      "C": "usual clinical care",
      "O": "difference in HbA1c level at week 36"
    },
    "NCT04692220": {
      "P": "patients, healthcare institutions, at-risk patients",
      "I": "new activities, medication reconciliation, ade detection activities, drug management, expanded development",
      "C": "different care services, pharmaceutical resources available",
      "O": "drp, ade, morbidity, health costs, harm, prevention"
    },
    "NCT02206074": {
      "P": "individuals with type 2 diabetes (T2D)",
      "I": "dietary nitrate supplementation",
      "C": "normal beetroot juice vs nitrate depleted beetroot juice",
      "O": "amount of oxygen required for exercise, ability to perform daily tasks comfortably, and brain function"
    },
    "NCT06309082": {
      "P": "patients with diabetic foot ulcers (DFU)",
      "I": "high-frame-rate ultrasound imaging technology and high-frequency contrast-enhanced ultrasound (H-CEUS) technology",
      "C": "ulcerated sites vs normal sites",
      "O": "visualization of microcirculation in ulcer wounds"
    },
    "NCT03312582": {
      "P": "type 2 diabetes mellitus patients",
      "I": "metformin gel manual debridement",
      "C": "placebo manual debridement",
      "O": "efficacy"
    },
    "NCT02553382": {
      "P": "patients with type 2 diabetes already receiving conventional treatments",
      "I": "co-administration of viscous dietary fibre blend, salba grain rich in omega-3 fatty acids, and 2 varieties of ginseng roots, in addition to usual treatment regimen",
      "C": "usual treatment regimen",
      "O": "improve blood sugar control, cardiovascular disease risk outcomes"
    },
    "NCT00988182": {
      "P": "healthy young adults",
      "I": "whey protein hydrolysate",
      "C": "none (single intervention)",
      "O": "satiety, blood glucose, insulin"
    },
    "NCT04573920": {
      "P": "patients with proteinuric glomerular disease and risk of progressive loss of renal function",
      "I": "atrasentan",
      "C": "open-label basket study vs. unknown",
      "O": "efficacy and safety"
    },
    "NCT04247620": {
      "P": "young adults age 17-25",
      "I": "strengths-based peer support intervention",
      "C": "transition pediatric adult diabetes care",
      "O": "glycemic control, adherence, psychosocial outcomes"
    },
    "NCT03175120": {
      "P": "Chinese subjects with type 2 diabetes mellitus",
      "I": "Insulin degludec/liraglutide",
      "C": "Insulin degludec",
      "O": "Controlling glycaemia"
    },
    "NCT00727220": {
      "P": "young children with type 1 diabetes, 40 children with IDDM, 5 years of age, 10 patients",
      "I": "insulin pumps, basal glargine, NPH, Lente, rapid-acting insulin",
      "C": "children utilizing insulin pumps vs. children using multiple daily injections",
      "O": "glycemic outcomes, overall control, blood sugar variability, cognitive outcomes, parenting stress, changes in diet"
    },
    "NCT01798420": {
      "P": "diabetic patients admitted with COPD exacerbation",
      "I": "corticosteroid treatment",
      "C": "no comparison mentioned",
      "O": "expected increase in hemoglobin A1c levels"
    },
    "NCT05983120": {
      "P": "type 2 diabetes mellitus individuals",
      "I": "study conducted order study effect training given according social-cognitive learning theory sclt upon diabetes self-management quality life",
      "C": "none",
      "O": "quality life"
    },
    "NCT01722682": {
      "P": "T1D patients",
      "I": "Islet transplantation",
      "C": "BM (bone marrow) vs Liver sites",
      "O": "Safety and efficacy"
    },
    "NCT04407182": {
      "P": "patients with mild to moderate symptoms of respiratory disease caused by the 2019 coronavirus infection",
      "I": "Viusid (30 ml) and Asbrip (10 ml) administered orally every 8 hours",
      "C": "standard care",
      "O": "safety and efficacy"
    },
    "NCT02344082": {
      "P": "patients with hemoglobin A1c greater than 9% who are eligible and have a primary care physician at Johns Hopkins Outpatient Center (JHOC) or East Baltimore Medical Center (EBMC)",
      "I": "face-to-face pharmacy clinic visits plus additional telephone follow-up",
      "C": "standard care",
      "O": "change in hemoglobin A1c at 3 months"
    },
    "NCT06269120": {},
    "NCT00759720": {
      "P": "patients with type 2 diabetes",
      "I": "tak-559 daily qd combined with glyburide",
      "C": "no comparison specified",
      "O": "safety and efficacy"
    },
    "NCT05377320": {
      "P": "cancer survivors",
      "I": "novel clinical decision aid accessed via electronic health record",
      "C": "cardiologists",
      "O": "improve clinician patient decision-making perception behavior towards cardioprotective medication usage cardiovascular disease imaging utilization"
    },
    "NCT01464320": {
      "P": "subjects with type 2 diabetes and chronic kidney disease",
      "I": "ABT-614",
      "C": "no comparison specified",
      "O": "glomerular filtration rate"
    },
    "NCT05092620": {
      "P": "participants enrolled",
      "I": "collection",
      "C": "storing",
      "O": "data"
    },
    "NCT03015220": {
      "P": "Japanese subjects with type 2 diabetes",
      "I": "Oral semaglutide and dulaglutide combination",
      "C": "Oral semaglutide versus dulaglutide",
      "O": "Safety and efficacy"
    },
    "NCT02180620": {
      "P": "patients with medications prescribed",
      "I": "exercise (pre-dinner vs post-dinner)",
      "C": "pre-dinner vs post-dinner",
      "O": "post-dinner glucose and triglyceride levels"
    },
    "NCT01646320": {
      "P": "patients with type 2 diabetes",
      "I": "dapagliflozin as part of triple combination therapy",
      "C": "2 drug oral antidiabetic therapy",
      "O": "improve decrease hemoglobin A1c"
    },
    "NCT04658082": {
      "P": "patients with type 2 diabetes",
      "I": "gwave non-invasive glucometer",
      "C": "core lab glucose measurement",
      "O": "accuracy of non-invasive glucose monitor"
    },
    "NCT02408120": {
      "P": "patients with type 2 diabetes hospital already receiving standard care treatment",
      "I": "using extra doses aspart insulin",
      "C": "standard treatment with glargine aspart insulin injections",
      "O": "correct blood sugars"
    },
    "NCT02947620": {
      "P": "subjects with type ii diabetes and dyslipidemia",
      "I": "metformin/atorvastatin",
      "C": "active-controlled",
      "O": "safety and efficacy"
    },
    "NCT02023320": {
      "P": "subjects with prediabetes",
      "I": "blueberry dry powder",
      "C": "no comparison mentioned",
      "O": "effect on glycemic status, fasting plasma glucose, 2h glucose concentration, oral glucose tolerance test (OGTT), HbA1c"
    },
    "NCT06049420": {
      "P": "developed nations, rural populations, patients with chronic diseases",
      "I": "lifestyle medicine, physical activity, yoga studio, martial arts, fitness facilities, aquatic center, exercise techniques, equipment",
      "C": "pharmaceutical therapies, lack of access to health clubs and wellness programs",
      "O": "decrease in quality of life, death, rates of disease onset, chronic diseases"
    },
    "NCT01537120": {
      "P": "patients with type 2 diabetes",
      "I": "twice daily administered dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin",
      "C": "new existing pharmacological treatments",
      "O": "24 hour weighted-mean glucose (WMG)"
    },
    "NCT04499820": {
      "P": "patients with minimal to moderate non-proliferative diabetic retinopathy",
      "I": "omega 3 supplementation",
      "C": "no comparison specified",
      "O": "macular capillary density measured by optical coherence tomography angiography"
    },
    "NCT01073020": {
      "P": "clinically severe obese patients, class 3 obesity, moderately obese population, class 1 2 obesity",
      "I": "bariatric surgical procedures, multidisciplinary intensive medical weight management treatment",
      "C": "currently practiced available bariatric surgical procedures, multidisciplinary intensive medical weight management treatment",
      "O": "improve metabolic control, resolve type 2 diabetes, insulin secretion, insulin action, weight loss"
    },
    "NCT02744820": {
      "P": "healthy subjects, type 2 diabetics",
      "I": "multiple oral doses of GMC-252-L-lysine salt",
      "C": "none mentioned",
      "O": "safety, tolerability, pharmacokinetics, pharmacodynamic parameters"
    },
    "NCT02331420": {
      "P": "obese patient affected type 2 diabetes",
      "I": "bariatric surgery, optimal medical therapy",
      "C": "bariatric surgery vs optimal medical therapy",
      "O": "endothelial function, subclinical atherosclerosis, cardiovascular autonomic function"
    },
    "NCT04025320": {
      "P": "graduate student with diabetes mellitus type 2 (DMT2) and moderate to severe ankle neuropathy symptoms",
      "I": "intraneural facilitation (INF) treatment",
      "C": "no comparison mentioned",
      "O": "significant improvements in blood flow, pain, sensation, and overall quality of life"
    },
    "NCT06481020": {
      "P": "overweight/obese type 1 2 normoglycemic/pre-diabetic",
      "I": "ps-containing food supplement",
      "C": "placebo supplement",
      "O": "ldl-cholesterol values 115 mg/dl"
    },
    "NCT00656682": {
      "P": "type 2 diabetes",
      "I": "group-based lifestyle intervention",
      "C": "free-of-charge access",
      "O": "prevention"
    },
    "NCT06169982": {
      "P": "participants with type 2 diabetes mellitus",
      "I": "ly3209590",
      "C": "no comparison mentioned",
      "O": "measure of activity or insulin action at steady state"
    },
    "NCT02440282": {
      "P": "diabetic foot patients",
      "I": "sciatic nerve block",
      "C": "general spinal anesthesia",
      "O": "hemodynamic stability, postoperative pain"
    },
    "NCT06532682": {
      "P": "patients with type 1 diabetes (T1DM) and type 2 diabetes (T2DM) with diabetic kidney disease (DKD)",
      "I": "dapagliflozin combined with insulin",
      "C": "standard treatment with ACE inhibitors (ACEI) and Angiotensin Receptor Blockers (ARB)",
      "O": "kidney protection"
    }
  }